Oxford Global proudly presents two of its upcoming flagship events under the Precision Medicine brand, each designed to drive progress through interdisciplinary learning, cutting-edge science, and cross-sector collaboration. Together, Biomarkers & Precision Medicine 2025 (Europe) and Biomarkers & Precision Medicine US 2025 offer a powerful platform to explore how multi-omics, AI, biomarkers, CDx, spatial biology and digital pathology are converging to transform diagnostics, therapeutics, and patient outcomes.
Celebrating its 20th anniversary, Biomarkers & Precision Medicine 2025 in London stands as Europe’s leading event for biomarker innovation in drug discovery, development, clinical trials, and precision medicine. This landmark edition brings together over 1,000 attendees from pharma, biotech, academia, and regulatory institutions for two days of in-depth scientific exchange and high-level networking.
Structured around 16 content tracks and three dedicated programmes—Biomarkers, Spatial Biology for Precision Medicine, and Digital Pathology & AI—the agenda reflects the expanding complexity of precision medicine and the technologies driving its evolution. From companion diagnostics and IVDR regulations to AI-powered biomarker analysis and digital pathology workflows, attendees will gain insights into tools shaping clinical decision-making, patient stratification, and drug response monitoring.
Highlights include a keynote by Matthew Brown, Chief Scientific Officer at Genomics England, who will speak on the transformative role of multiomics in rare disease diagnostics. Additional speakers include senior leaders from AstraZeneca, Roche, ETH Zurich, and a special fireside chat with Sir Mark Caulfield, who will reflect on his contributions to genomic medicine and its future trajectory.
Complementing the main programme are Collaboration Hubs - invitation-only sessions designed to encourage small-group dialogue on regulatory strategy, AI integration, and clinical implementation. These focused interactions support Oxford Global’s mission of breaking down silos and fostering practical solutions through interdisciplinary engagement.
Whether you're focused on spatial biology for precision medicine, AI-powered biomarker analysis, or biomarker identification and validation for CNS research, this is your opportunity to engage with those leading the next generation of diagnostics and therapeutic development. Biomarkers & Precision Medicine 2025 is not just a meeting - it is a collaborative platform for accelerating discovery and delivering on the promise of personalised medicine.
One month later, the conversation continues at Biomarkers & Precision Medicine US 2025 in San Francisco. As Oxford Global’s premier U.S. gathering for translational innovation, this event brings together over 1,000 precision medicine leaders, more than 30 partners, and more than 10 hours of pre-arranged 1-to-1 meetings in a dynamic setting tailored for collaboration and discovery.
Mirroring its European counterpart, the U.S. meeting features core programmes -Biomarkers, Spatial Biology for Precision Medicine, and Digital Pathology & AI - with 13 content tracks addressing every stage of the biomarker and precision medicine pipeline. Attendees will delve into companion diagnostics, clinical development strategies, real-world AI integration, and the clinical application of multi-modal data.
The keynote line-up includes visionary systems biologist Dr. Leroy Hood, co-founder of the Institute for Systems Biology, who will discuss the convergence of data-led healthcare and peptide drug discovery. Dr. Ida Sim (UCSF/UC Berkeley), a pioneer in computational precision health, will explore real-world applications of AI, predictive modelling, and data ethics. The programme also features track keynote contributions from senior figures at Amgen, GSK, MD Anderson Cancer Center, Moffitt Cancer Center, and UCLA.
Interactive panel sessions will address the implementation of digital pathology, spatial transcriptomics, and proteomic biomarkers, alongside high-level discussions on IVDR regulations, AI integration, and patient-centric clinical trial design. These sessions - along with real-world use cases and forward-looking discussions - underscore the central theme of this year’s US meeting: layering multi-omics with cutting-edge technologies to deliver meaningful advances in patient care.
A Unified Vision for Precision Medicine
Together, these two events form a powerful global platform dedicated to advancing the next era of biomarker science and personalised healthcare. Across both London and San Francisco, attendees will engage with key opinion leaders, emerging biotech innovators, and cross-functional teams solving shared challenges across therapeutic areas including oncology, immunology, neuroscience, and rare diseases.
With a strong focus on interdisciplinary collaboration, both editions of Biomarkers & Precision Medicine 2025 offer attendees not just content - but connection: curated environments where knowledge-sharing and cross-sector innovation drive the future of precision healthcare forward.
Join us in London or San Francisco - or both - to be part of the global movement transforming diagnostics and therapeutics for a new era of medicine.